Minoryx is a clinical stage biotech company leading the development of new therapies for X- ALD and other rare diseases with a high unmet medical need. The company’s leading program is MIN-102, which has potential for multiple CNS indications beyond X-ALD. The Minoryx team consists of a group of drug discovery and development experts with several decades of experience in biotech and pharma. The company is backed by a syndicate of experienced investors and has support from a network of other organizations. Minoryx was founded in 2011 and has raised a total of €50M.
Aelin Therapeutics is founded by VIB and its partner universities KU Leuven, VUB and UGent, based on the groundbreaking work of renowned structural biologists Prof Joost Schymkowitz and Prof Frederic Rousseau. The company is based on a very comprehensive preclinical Proof of Concept data package illustrating different applications of the technology such as in bacteria and cancer cells, but also in fungi, viruses and plant cells, with publications in high impact journals including Science. The Pept-in technology allows for the rational design of novel biotherapeutics and differentiates itself from any other therapeutic modality through its unique mode of action, its designability and intracellular target space out of reach for typical small molecule or antibody approaches.
Horama is a clinical-stage biotech company that develops gene-therapy treatments, based on recombinant adeno-associated virus (rAAV) vectors, targeting rare inherited retinal diseases. Horama was founded in 2014 by a complementary team of world-renown academic researchers who conducted, in 2011, one of the first clinical trials of gene therapy applied to ophthalmology in France, including: Philippe Moullier, Christian Hamel (1955-2017) and Vasiliki Kalatzis, from the French National Institute of Health and Medical Research (INSERM); and Michel Weber and Guylène Le Meur, from the Nantes University Hospital in France.
Immunic AG is clinical stage biotech company founded in 2016 and focused on the development of immune modulators to block Th17 and Th1-mediated immune and autoimmune responses. The company’s two development programs include orally available, small molecule inhibitors of DHODH (IMU-838 program) and inverse agonists of RORγt (IMU-366 program) relevant to diseases such as ulcerative colitis, Crohn’s disease and psoriasis. The final aim is to develop these drug candidates to clinical proof of concept. Immunic, with headquarters in Planegg-Martinsried near Munich, Germany, is privately held and supported by several renowned sector investors.
OCTIMET Oncology NV is a new company that acts as a translational accelerator, focusing on creating value for investors and patients by providing rapid clinical proof of concept for cancer therapies through innovative clinical development strategies and patient centered biomarker approaches. OCTIMET was set-up in 2016 and is run by a highly experienced management team. The current focus is on its clinical stage asset OMO-1, a highly selective small molecule MET inhibitor that will be developed with specific biomarkers, whilst an additional late pre-clinical stage oncology asset 0MO-2 will also enter the portfolio. (www.octimet.com)
eTheRNA was established in January 2013 as a spin-off company of the ‘Vrije Universiteit Brussel’ (VUB), following the development of the TriMix technology by the VUB Laboratory for Molecular and Cellular Therapy, headed by Prof. Kris Thielemans (and co-founders Carlo Heirman and Sonja van Meirvenne) in tandem with Prof Bart Neyns from the Brussels University Hospital ‘UZ Brussel’.
In 2015, eTheRNA entered into a partnership with Progress Pharma under the leadership of Dirk Reyn, former CEO of Movetis, who now heads eTheRNA immunotherapies management team. In July of that year, eTheRNA obtained from the VUB a worldwide exclusive license on the TriMix technology.
In March 2016, eTheRNA immunotherapies secured EUR 24 million in a Series, an investment with a strong international syndicate of investors.
This enables the company to continue the development of mRNA-based immunotherapies for melanoma, triple negative breast cancer and infectious diseases.
Established in 2013, Novadip BioSciences is a biomedical spin-off company from the University of Louvain (UCL, Belgium) and its academic hospital, (Cliniques universitaires Saint-Luc). Novadip’s mission is to develop and bring to the market innovative treatments for large bone defects. The creation of NOVADIP is supported by the Louvain Technology Transfer Office (LTTO), Sopartec and VIVES II.
The lead product candidate of the Company is CREOST®
CREOST® introduces the principles of guided tissue regeneration based on stem cells from fatty tissue, associated to osteoinductive, osteoconductive and osteogenic properties to manufacture natural bone implants with the right shape, mineralization and all mechanical properties for replacement and repair of large bone defects.
CREOST® holds the potential for multiple indications including neurosurgery for spine, orthopaedic surgery for trauma, pseudarthrosis or tumour resection, cranial and maxillofacial surgery, Osteonecrosis, consequences of osteoporosis, etc.
iTeos Therapeutics is a private biotechnology company targeting metabolism of the tumor microenvironment to develop small molecule immunomodulators for cancer treatments. iTeos is building its activities upon the unparalleled expertise of the Ludwig Cancer Research (LICR) – a world-class Research Institute in the fields of tumor immunology, therapeutic cancer vaccines, cancer biology and translational medicine in cancer. iTeos endeavours to develop small molecules designed to target the tumor microenvironment by inhibiting cancer-induced immune suppression. Targeting such resistance mechanisms will enhance the clinical efficacy of both standard of care treatments as well as the newer immunomodulatory therapies based on the blockade of immune checkpoints (e.g. anti-CTLA4, anti-PD1 and anti-PDL1 antibodies). Based in Gosselies, Belgium iTeos is a private company launched in 2012 as a spin-off of the Ludwig Cancer Research (LICR) and the de Duve Institute at the Université catholique de Louvain. iTeos raised €9,1M in 2012 from private investors, including LICR, Life Sciences Research Partners, Vives II, Hunza Ventures SCA, several high net worth individuals and from a Walloon government grant.
Promethera® Biosciences is a Belgian pharmaceutical company, spin-off of the Université Catholique de Louvain, that develops innovative treatment based on allogeneic adult stem cell technology. Promethera® Biosciences’ mission is to discover, develop, and commercialize cell therapy products to treat liver diseases in an innovative way using allogenic progenitor cells harvested from healthy human livers. Promethera® Biosciences develops two products based on a newly discovered and patented progenitor cell type, the Heterologous Human Adult Liver Progenitor Cell (HHALPC):
- Promethera® HepaStem, a unique cell therapy product, to treat severe diseases of the liver affecting children and adults. The innovation resides in both the simplicity of the treatment, which doesn’t require radical surgery (compared to liver transplantation), and in the wide variety of liver diseases that can be addressed with the same product.
- Promethera® H2Screen and H3Screen, a unique cell model for the pharmaceutical industry to mimic metabolism and detoxification of new drugs by the human liver. The cell model is designed for the discovery and pre-clinical evaluation of new chemical entities.
Ogeda S.A. was acquired by Astellas in April 2017.
Q-Biologicals was acquired by the French Amatsi Group in January 2016.